MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jvir.2026.108910

Медицинская библиотека · Journal of vascular and interventional radiology : JVIR · 2026

Comparison of 3-Year United States Payer Costs for Endovascular Treatment Options to Treat Femoropopliteal Artery Disease.

Lyden Sean P, Bavière Henri Vanden, Martinson Melissa, Wheatley Margo, Tarra Trisha, Gray William A

СтатьяСравнительное исследованиеПеревод в очереди

Аннотация

PURPOSE: To assess costs and cost effectiveness of bare metal stent (BMS), drug-eluting stent (DES), and paclitaxel drug-coated balloon (DCB) relative to percutaneous transluminal angioplasty (PTA) for treatment of femoropopliteal peripheral artery disease (PAD) in the United States.

MATERIALS AND

METHODS

An economic model was developed to assess the 3-year cost and cost effectiveness from a U.S. payer perspective of PTA, BMS, DES, and paclitaxel DCB. Model inputs were derived from the literature. Costs were obtained from 2023 U.S. Medicare national-mean rates and included hospital outpatient and physician reimbursement. The authors used Medicare national-mean rates to reflect costs to the Medicare system. Sensitivity analyses evaluated the impact of bailout stent and target lesion revascularization (TLR) rates on results.

RESULTS

The estimated mean per-person costs for endovascular procedures over 3 years were $9,151 for PTA, $13,325 for BMS, $13,054 for DES, and $8,406 for DCB. U.S. Food and Drug Administration (FDA)-approved DCBs showed comparable economic value, with costs between $8,027 and $8,804 for IN.PACT Admiral, Stellarex, Lutonix, and Ranger devices. Incremental quality-adjusted life years (QALYs) gained were between 0.0035 and 0.0054 for strategies compared with PTA. DCBs were cost-saving, whereas BMS and DES were not cost-effective with incremental cost-effectiveness ratios > $150,000/QALY gained. The sensitivity analysis results showed that PTA and DCB bailout stent rates had the largest impact on costs; however, DCBs remained cost-saving in most cases.

CONCLUSIONS

DCBs provided a moderate cost-savings in endovascular procedure costs over PTA due to lower TLR rates over 3 years. DES and BMS were not cost-effective from a U.S. payer perspective despite similar TLR rates as DCBs due to higher reimbursement levels and minimal gains in QALYs.

Для цитирования: Lyden Sean P, Bavière Henri Vanden, Martinson Melissa, Wheatley Margo, Tarra Trisha, Gray William A. Comparison of 3-Year United States Payer Costs for Endovascular Treatment Options to Treat Femoropopliteal Artery Disease.. Journal of vascular and interventional radiology : JVIR. 2026. DOI: 10.1016/j.jvir.2026.108910.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.